140. Dorabe syndrome Clinical trials / Disease details
Clinical trials : 116 / Drugs : 65 - (DrugBank : 17) / Drug target genes : 50 - Drug target pathways : 64
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02091375 (ClinicalTrials.gov) | March 30, 2015 | 17/3/2014 | Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) | A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome | Epilepsy;Dravet Syndrome | Drug: GWP42003-P 20 mg/kg/day Dose;Drug: Placebo control | Jazz Pharmaceuticals | NULL | Completed | 2 Years | 18 Years | All | 120 | Phase 3 | United States;France;Poland;United Kingdom |
| 2 | NCT02091206 (ClinicalTrials.gov) | October 22, 2014 | 17/3/2014 | A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) | A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome | Epilepsy;Dravet Syndrome | Drug: GWP42003-P 5 mg/kg/day Dose;Drug: Placebo control;Drug: GWP42003-P 10 mg/kg/day Dose;Drug: GWP42003-P 20 mg/kg/day Dose | Jazz Pharmaceuticals | NULL | Completed | 4 Years | 10 Years | All | 34 | Phase 2 | United States;United Kingdom |